For example, while the top-ranked tumor-enriched fusion, FGFR3::TACC3 (rank 1, 70 tumor samples, 0 normal) is a known oncogenic driver,36 other top-ranking fusions, such as CCAT1:CASC8 (rank 2, 42 tumors—mostly lung and stomach cancers, 0 normal) and VCL::ADK (rank 3, 36 tumors—also mostly lung and stomach cancers, 0 normal) have not yet been extensively studied. This evidence concerns the gene FGFR3 and gastric neoplasm.